Database

Startups

Main Industry
Biotechnology
Main Product/Service
Primo’s products and services include radioligand therapeutic agents, tumor‑molecular imaging diagnostics (such as PB01 / [¹⁸F]PSMA‑1007 for prostate cancer), and imaging‑platform plus manufacturing services supporting clinical trials. The company has als
Founded Year
2021
Unified Business No.
90712775
Status
Active
Number of Employees
0
Total Paid-in Capital
584,760,228 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
Primo Biotechnology Co., Ltd., headquartered in Taipei, focuses on the development and manufacturing of precision medicine and radioligand theranostics (RLT). The company is committed to leveraging molecular imaging and radiopharmaceutical technologies to improve cancer diagnostics and therapy, with the vision "Future in Precision."



More ↓

Similar Companies

EVERFRONT BIOTECH INC.

1. EF-001 (Cerebraca® Wafer)
2. EF-009 Wafer
3. HK-001
4. EF-031
5. TSCA-001
6. EF-011

Great Novel Therapeutics Biotech & Medicals Corporation

GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.

Anbogen Therapeutics, Inc.

Anbogen’s drug pipeline features two lead small‑molecule candidates: “ABT‑101,” a tyrosine kinase inhibitor targeting HER2 exon20 insertion mutations in non‑small cell lung cancer; and “ABT‑301,” an HDAC1/2/3 inhibitor designed for combination therapy wit